What's Happening

Search Results

Access to PrEP is changing minds and behaviors. As an HIV prevention option, PrEP (pre-exposure prophylaxis for HIV) has provided individuals who may be at risk for HIV an important tool in the way they conceptualize choices about sex partners.

The practice of serosorting—selecting a sexual partner based on HIV status—has often been seen as either stigmatizing or divisive. However, PrEP is changing this practice among both older and younger men who have sex with men (MSM). I contributed to a just-published paper that demonstrates this in some persuasive ways.

STD rates are up. The CDC noted in a recent press release that reported STDs are at an “unprecedented high” in the U.S.

This sort of news is undeniably discouraging for those of us working the sexual and reproductive health arena. After all, we’ve been feeling rather upbeat and hopeful about the impressive drop in unplanned teen pregnancies—rates are down more than half over the past 20 years.

PrEP has altered the landscape in HIV prevention in extraordinary and profound ways. It’s changing the lives of vulnerable individuals. It’s also bringing about big changes for the HIV workforce—health care providers, prevention specialists, outreach workers, social workers, educators and more. In fact, I believe we’ve entered the most dynamic period in our fight against HIV since 1996, when the advent of highly active antiretroviral therapy revolutionized treatment and saved countless lives.

In 2012, the U.S. Food and Drug Administration approved oral Truvada for pre-exposure prophylaxis of HIV (PrEP). In a very short period of time, PrEP has substantially changed the HIV prevention landscape. It’s effective (when taken) and has an excellent safety profile.

How well is it working in different populations? I took a quick dive into some recent reports to get an update.

PrEP (pre-exposure prophylaxis) for HIV means taking a combination pill to prevention transmission of the virus. The pill, brand name Truvada, has proved to be successful at protecting at-risk individuals. Trials evaluating PrEP among gay and bisexual men, heterosexual men and women, and injection drug users indicate that the risk of getting HIV decreased by up to 92% for participants who took the medicine consistently.